Human pharmacogenetic analysis in chimeric mice with 'humanized livers'

Pharmacogenetics and Genomics

Volumn 23, Issue 2, 2013, Pages 78-83

  Hu, Yajing ^a   Wu, Manhong ^a   Nishimura, Toshihiko ^a   Zheng, Ming ^a   Peltz, Gary ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chimeric mice; drug metabolism; pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DICLOFENAC; DRUG METABOLITE; MEPHENYTOIN; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG METABOLISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TRANSGENE;

MUS;

EID: 84873097181     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835cb2c7     Document Type: Article

References (26)

1. Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, et al. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011; 10:817-833.
2. Guo Y, Shafer S, Weller P, Usuka J, Peltz G. Pharmacogenomics and drug development. Pharmacogenomics 2005; 6:857-864.
3. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483:613-617.
4. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3:739-748.
5. Anderson S, Luffer-Atlas D, Knadler MP. Predicting circulating human metabolites: how good are we? Chem Res Toxicol 2009; 22:243-256.
6. Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, et al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 2009; 22:1653-1662.
7. Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 2009; 22:280-293.
8. Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, et al. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 2011; 405:405-410.
9. Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 2009; 5:1435-1446.
10. De Jong YP, Rice CM, Ploss A. New Horizons for studying human hepatotropic infections. J Clin Invest 2010; 120:650-653.
11. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma (c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100:3175-3182.
12. Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, et al. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 2012 (in press).
13. Sparidans RW, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872:77-82.
14. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-958.
15. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328-332.
16. Zhou HH. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 2001; 313:203-208.
17. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-263.
18. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192:23-32.
19. Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003; 59:221-225.
20. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30:471-475.
21. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010; 20:277-281.
22. Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9&z.ast;3 allele. Eur J Clin Pharmacol 2000; 56:65-68.
23. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55:51-61.
24. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, et al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 2009; 22:357-368.
25. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481:295-305.
26. Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med 2011; 3:82ra39.